BMY241129P56000
- 0.03
- 0.000.00%
Bristol-Myers Squibb Newsroom
Express News | Bristol-Myers Squibb's three innovative drugs have been included in the 2024 National Medical Insurance Catalog.
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
Bristol-Myers Squibb Hits 14-month High
Merck Phase 3 Study of Winrevair in PAH Meets Primary Endpoint
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Replimune Climbs After Updates on Lead Drug
Optimism Over Global Healthcare Sector Rises: Jefferies
Investing in Bristol-Myers Squibb (NYSE:BMY) a Year Ago Would Have Delivered You a 24% Gain
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Today's Analyst Rating | NVIDIA Price Target Raised to $180 by Stifel, BMO Capital Cuts Its Price Target Cut on Eli Lilly and Co to $1010
Nov 19, Wall Street analysts have updated their stock ratings today including $NVIDIA(NVDA.US)$ and $Eli Lilly and Co(LLY.US)$.
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
Express News | Bristol Myers Squibb’s Presentations at Ash 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Wells Fargo Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60